PARP inhibitors are being explored clinically in several other types of cancer that exhibit HRD. A few examples are presented here, but additional trials are continually being added to clinical trial registries.
Niraparib, olaparib and rucaparib are all being investigated in advanced endometrial cancer.
In the monotherapy setting, a phase II study is investigating niraparib in patients with recurrent endometrial cancer, regardless of PTEN status (NCT03016338).
In the maintenance setting, both olaparib and rucaparib are being explored following treatment with chemotherapy in patients with metastatic and/ or recurrent endometrial cancer. A randomised phase II study is assessing the benefit of rucaparib versus placebo after 1-2 prior lines of therapy (NCT03617679), and a randomized, double-blinded study (UTOLA; NCT03745950) is underway of olaparib versus placebo. Results from these trials are expected in 2022 or beyond.
Rucaparib monotherapy is being assessed in patients with locally-advanced unresectable or metastatic urothelial carcinoma (ATLAS trial; NCT03397394).
The phase II PLATFORM trial (NCT02678182) is studying several maintenance treatments, including rucaparib, for patients with locally advanced or metastatic HER-2 positive or HER-2 negative gastroesophageal cancer following completion of standard first-line chemotherapy.